Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
about
Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cellsAllogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapseNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioNCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaComparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.Prior exposure to imatinib does not impact outcome of allogeneic hematopoietic transplantation for chronic myeloid leukemia patients: a single-center experience in chinaChronic myelogenous leukemia: role of stem cell transplant in the imatinib era.The role of stem cell transplantation for chronic myelogenous leukemia in the 21st centuryHow I treat childhood CML.Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcomeA disease risk index for patients undergoing allogeneic stem cell transplantation.Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors.Role of allo-SCT for CML in 2010.Stem cell transplant for chronic myeloid leukemia in the imatinib eraTreatment of chronic myeloid leukemia when imatinib fails.Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Allogeneic transplantation for CML in the TKI era: striking the right balance.Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.Allogeneic transplant for chronic myeloid leukemia in 2010.Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry.Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
P2860
Q28484493-8A7E9278-3443-4C3B-AF46-CE606842A48BQ33747792-502A2738-9CAA-4F82-8A84-BCC85920BDA0Q33750753-423A5E6A-1051-46F6-8B0F-9FF2B183A41CQ33813443-13766568-3DCB-4390-832F-18F980B7F59BQ34087133-E431B8BF-E52E-465E-BC61-94E3D71F4CF9Q34202277-1A580C8B-D2C1-4728-9606-8A32F3B764BDQ34522789-816B995D-4628-44A6-9B76-F3E45B5C7FC9Q35085078-1A558A54-EB82-40C9-A8C7-C4B66ECF5760Q35480678-C46589C2-EC6A-468D-A468-812BEB1E1DDFQ35633858-11BCA856-C2ED-48CD-BDC1-D2CC4B6F993FQ35634865-9CDFBC87-4747-434A-9B2C-D3D9331DC010Q35802202-BFBE343A-8E16-48FB-B19F-8B323D027B77Q36059184-EE141F9E-6E86-4C7F-9147-AB01836DB015Q36141944-ECBB7B15-AF53-44DA-9533-11A720568439Q36364850-D98647D9-3A49-4583-8D81-FB2D2118EF9BQ37148391-4D4602A5-CE4B-4655-AA62-2697A052891CQ37163550-2F7B30E8-8810-4AE6-9988-32DC8BE07456Q37428659-45901F38-565D-46C1-90EE-C279349E639BQ37428676-61F50AD5-9EC2-482C-BAB2-F31D37C39BC6Q37497977-B51106CD-8B4A-4158-96E0-D6E7F5428657Q37657492-E0BE94B7-3E9B-4F28-8E37-84E4877E5B8BQ37763493-F29FD2FA-23A5-4A61-8D55-566000BAA354Q37793491-136586B7-1A26-433F-AE29-F9D77CEF54FFQ37827875-0786C49A-661D-411D-B0E2-DA2B97B8D38BQ37853793-5A71160E-4385-4EE3-BD1C-2B66A3B42BA8Q38216677-A6000B76-DDA8-49F8-9055-DACD22D742D4Q38236642-5A15B37B-29D3-4315-A018-5F157EFA7E61Q38392690-1995F7FD-2D0D-4D7A-A72F-D3F6B4F74A28Q38585916-CFCE74DD-546E-486E-A7B8-C5173ED45D41Q38634736-39195FA1-BDFD-454E-80B4-41D899DED6EDQ38757051-439F64CB-A010-481C-9734-A117D80A258BQ38764223-ABB6CDE8-F750-4038-93B5-A022597ADD7BQ39307476-F42759C3-C037-4285-ACF6-BE45C81C0043Q39464336-5B2BACED-0946-4C51-8C8F-2C9B67DDA061Q40539487-809D810B-7987-4179-8E9B-0EB54A257175Q40957470-7A9CC49B-DB2D-4E85-9587-325E08C3876BQ41874881-47E72757-6BFC-42DE-825A-E49E612D8667Q42203455-A0C0FD59-DBEB-47E8-BEDD-F7DC23A56523Q45871441-431B4632-5F8E-4C9F-91CE-080EF5473FA5Q46737739-F5167DFC-8FBB-41C7-BAF5-E96F2A1D6FB6
P2860
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@ast
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@en
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@nl
type
label
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@ast
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@en
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@nl
prefLabel
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@ast
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@en
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@nl
P2093
P2860
P1433
P1476
Impact of prior imatinib mesyl ...... for chronic myeloid leukemia.
@en
P2093
Ann E Woolfrey
Armand Keating
Axel R Zander
Biju George
Brian J Bolwell
David A Rizzieri
David I Marks
Eduardo Olavarria
Edward A Stadtmauer
Edward Copelan
P2860
P304
P356
10.1182/BLOOD-2008-02-141689
P407
P577
2008-07-29T00:00:00Z